Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI

Table 2

Lesion characteristics. Baseline size calculated as (T₁ + T₂)/2, size after therapy as (T₃ + T₄)/2. In four cases, the T₄ measurement was not available and therefore the diameter measured at T₃ used.

Characteristic	Patients ()
Lesions per patient
1	3
2	7
3	6
4	4
Size of the lesions, longest diameter
Baseline, mean (SD)	41 mm (27 mm)
After therapy, mean (SD)	36 mm (24 mm)
Lesion response
Regressive (number/mean diameter change)	18/−26.0%
Stable (number/mean diameter change)	26/−0.6%
Progressive (number/mean diameter change)	7/+10.3%